- Home
- ACHV vs PYXS Comparison
ACHV vs PYXS Comparison
Compare ACHV & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- PYXS
- Stock Information
- Founded
- ACHV N/A
- PYXS 2018
- Country
- ACHV Canada
- PYXS United States
- Employees
- ACHV N/A
- PYXS N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- ACHV Health Care
- PYXS Health Care
- Exchange
- ACHV Nasdaq
- PYXS Nasdaq
- Market Cap
- ACHV 72.5M
- PYXS 66.3M
- IPO Year
- ACHV N/A
- PYXS 2021
- Fundamental
- Price
- ACHV $3.35
- PYXS $1.17
- Analyst Decision
- ACHV Strong Buy
- PYXS Strong Buy
- Analyst Count
- ACHV 3
- PYXS 5
- Target Price
- ACHV $14.33
- PYXS $9.00
- AVG Volume (30 Days)
- ACHV 325.9K
- PYXS 405.6K
- Earning Date
- ACHV 08-12-2025
- PYXS 08-13-2025
- Dividend Yield
- ACHV N/A
- PYXS N/A
- EPS Growth
- ACHV N/A
- PYXS N/A
- EPS
- ACHV N/A
- PYXS N/A
- Revenue
- ACHV N/A
- PYXS N/A
- Revenue This Year
- ACHV N/A
- PYXS N/A
- Revenue Next Year
- ACHV N/A
- PYXS N/A
- P/E Ratio
- ACHV N/A
- PYXS N/A
- Revenue Growth
- ACHV N/A
- PYXS N/A
- 52 Week Low
- ACHV $1.84
- PYXS $0.83
- 52 Week High
- ACHV $5.31
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- ACHV 52.46
- PYXS 46.51
- Support Level
- ACHV $3.44
- PYXS $1.14
- Resistance Level
- ACHV $3.91
- PYXS $1.41
- Average True Range (ATR)
- ACHV 0.30
- PYXS 0.08
- MACD
- ACHV -0.09
- PYXS -0.02
- Stochastic Oscillator
- ACHV 28.03
- PYXS 12.73
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.